Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration‐Resistant Prostate Cancer

Approximately one‐third of patients with metastatic castration‐resistant prostate cancer (CRPC) exhibited primary abiraterone resistance. To identify alternative treatment for abiraterone nonresponders, we performed drug discovery analyses using the L1000 database using differentially expressed gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Sisi, Gao, Huanyao, Kim, Wootae, Zhang, Huan, Gu, Yayun, Kalari, Krishna R., Sinnwell, Jason P., Scholz, Jodi A., Xie, Fang, Yin, Ping, Yu, Jia, Qin, Bo, Zhuang, Yongxian, Wei, Lixuan, Tan, Winston, Bryce, Alan H., Weinshilboum, Richard M., Wang, Liewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124371/
https://www.ncbi.nlm.nih.gov/pubmed/35288936
http://dx.doi.org/10.1002/cpt.2582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124371/
https://www.ncbi.nlm.nih.gov/pubmed/35288936
http://dx.doi.org/10.1002/cpt.2582

Ejemplares similares